407

Ophthalmology Futures Retina & European Virtual Forums
Ophthalmology Futures Forums 2020

Ophthalmology Futures Retina & European Virtual Forums
Ophthalmology Futures Forums 2020

Datum
30.09.2020, 13:50 - 01.10.2020, 22:15
Sprache
Englisch
Gebühren ab
gebührenfrei
Veranstalter
Ophthalmology Futures Forum
Vision Futures Ltd.
Organisator

Ophthalmology Futures European Forum Secretariat
c/o Louise Richards (Managing Director), WBR Ltd
Vale House

Clarence Road
GB - TN1 1HE Tunbridge Wells
Fax: +44 (0)1892 512 180

 

Ophthalmology Futures Forums are clinician-driven innovation meetings focusing on new technology, entrepreneurial ventures, market access and other aspects of commercialisation in the ophthalmic healthcare sector. They cover all aspects of global innovation in ophthalmic devices, diagnostics and pharmaceuticals by connecting scientists, physicians, regulators, reimbursement specialists, corporate leaders, venture capitalists and other investors who support the advancement of eye care.
  • Basisinformation
    Datum
    30.09.2020, 13:50 - 01.10.2020, 22:15
    Sprache
    Englisch
    Gebühren ab
    gebührenfrei
    Veranstalter
    Ophthalmology Futures Forum
    Vision Futures Ltd.
    Organisator

    Ophthalmology Futures European Forum Secretariat
    c/o Louise Richards (Managing Director), WBR Ltd
    Vale House

    Clarence Road
    GB - TN1 1HE Tunbridge Wells
    Fax: +44 (0)1892 512 180

     

  • Programm
    PLEASE NOTE: Times listed below are local Amsterdam times.
    Please allow for the time difference in your location, for example:
    -1 hour London, – 6 hours Eastern, – 9 hours Pacific

    Retina Forum Provisional Programme, 30 September 2020

    12:30 - 12:40

    Welcome from the Co-chairs

    14:00 - 14:30

    Panel 1: Can AI Help Us Beyond Retinal Imaging?

    14:30 - 15:00

    Panel 2: Anti-VEGF Drugs for Retinal Disease: Is There Room for More?

    15:00 - 15:20

    A one to one with Marie-France Tschudin, President of Novartis Pharmaceuticals

    15:20 - 16:10

    Company Presentations 1

    16:10 - 16:40

    Panel 3: Gene and Cell-based Therapy for Retinal Disease: Opportunities and Challenges

    16:40 - 16:50

    Investment Overview

    16:50 - 17:20

    Panel 4: The Dream Versus the Reality: Making Investments in Retina, an Investor Perspective

    17:20 - 18:10

    Company Presentations 2 

    18:10 - 18:40

    Panel 5: Surgical Instrumentation and Microscopy: A Real Business or a Revenue Rounding Error 

    18:40 - 19:10

    Panel 6: Novel Drug Delivery Approaches for Posterior Segment Disease

    19:10 - 19:30

    A fireside chat with Dr Wiley Chambers, USFDA

    19:30 - 20:30

    Company Presentations 3 

    20:30 - 21:00

    Panel 7: The Impact of COVID-19 on Retina Discovery, Development and Business

    21:00 - 21:10

    Summary: Adnan Tufail

    21:10 - 21:15

    Concluding Remarks from the Co-chairs

    European Forum Provisional Programme, 01 October 2020
    12:30 - 12:40

    Welcome from the Co-chairs

    Keith Barton
    Kuldev Singh

    12:40 - 12:50 

    Market Overview

    Michael Giaquinto

    12:50 - 13:20 

    Panel 1: The Global Dry Eye Opportunity: Will it Ever be Realised?

    13:20 - 14:20

    Company Presentations 1

    14:20 - 14:50

    Panel 2: Big idea and No Money: Who Do I Call in a Big Company?

    14:50 - 15:10

    Leadership Perspective

    15:10 - 15:40

    Panel 3: Drug Delivery for Eye Diseases: Simply Cool Technology or also a Commercial Success?

    15:40 - 16:10

    Panel 4: Cataract and Other Elective Surgery in the Era of COVID-19

    16:10 - 17:10

    Company Presentations 2

    17:10 - 17:40

    Panel 5: Refractive Outcomes after Cataract Surgery: IOL Adjustment Vs Enhancement

    17:40 - 18:20

    Panel 6: Premium IOL Patient-reported Outcomes and Regulatory Processes

    Introductory talk and Discussion Panel

    Chair: Dr Malvina Eydelman

    18:20 - 19:20

    Company Presentations 3

    19:20 - 19:50

    Panel 7: Will Endothelial Damage Restrict Glaucoma Device Progression?

    19:50 - 20:20

    Panel 8: Investment Panel

    20:20 - 21:10

    Company Presentations 4

    21:10 - 21:40

    Panel 9: Investment Panel

    21:40 - 22:10

    A View from the Top: The Long-term Impact of COVID-19 on the Business of Ophthalmology

    Chair: James Mazzo

    22:10 - 22:15

    Summary and Concluding Remarks from Co-chairs

    Keith Barton
    Kuldev Singh

  • Gebühren
    Fachärzte/-innen
    Gebühren ab
    gebührenfrei
    Ärzte/-innen in Weiterbildung
    Gebühren ab
    gebührenfrei
    Sonstige
    Gebühren ab
    gebührenfrei
    (A saving of €800)
  • Buchung / Anmeldung

     

    Registration required. Please contact the organizer for further information.

  • Zertifizierung
    Keine Zertifizierung beantragt
  • Sponsoren
    Ora
    Carl Zeiss Ltd. (UK)
    Alcon UK
    Allergan UK
    Sight Sciences
    Novartis (US)
    REGENXBIO Inc.
    Aerie Pharmaceuticals Inc.
    GenSight Biologics Inc.
    Radiance Therapeutics Ltd
    Avellino Labs USA, Inc.
    LensGen Inc.
    Oculis Switzerland
    Beyeonics Surgical Ltd.
    Centricity Vision

Veranstaltung teilen